GLP-1 RAs ameliorate hepatic steatosis through improved insulin sensitivity, direct suppression of hepatic de novo lipogenesis through AMPK activation and SREBP-1c inhibition, and enhanced fatty acid oxidation through PPARα upregulation. Here, GCG is linked to fatty liver disease.